Redhill Biopharma Ltd.

Other

Paladin Labs Inc.

Orphelia Pharma

Bausch Health Companies Inc.

Patrick Gosselin

Thomas Julius Borody

Reza Fathi

Guy Goldberg

Gilead Raday

Aimesther Betancourt

Charles Uzarama

Bartholomew Weldon

Marie-Pierre Flament

Robert Vinson

Edward Kobus

Sandryne Dumoulin

Aimesther Ojito Betancourt

Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection byor the prevention of recurrence of disorders associated with infection by

All-in-one fixed-dose combination for treatinginfection

The present invention generally relates to liquid compositions and methods for treating oral inflammation by administering a liquid composition to the oral cavity. The liquid composition is prepared from a powder containing calcium glycerophosphate, one or more sodium phosphate salts, sodium chloride, and optionally sodium bicarbonate and silica. The powder is mixed with a quality of water to form a liquid that is supersaturated with calcium ions and phosphate ions and is essentially free of visible particles and precipitate.

Formulations of calcium and phosphate for oral inflammation

Rifabutin-based compositions and methods for treatinginfection

Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to,subspecies paratuberculosis infection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.

Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine

Methods for treating helicobacter pylori infection

Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.

Pharmaceutical compositions comprising lonafarnib and ritonavir

The invention pertains to a solid dosage form comprising vigabatrin; a superdisintegrant, advantageously chosen from the list consisting of crospovidone, a cellulose derivative and a starch derivative; a non-reducing sugar, advantageously chosen from the list consisting of mannitol, xylitol, and sorbitol; and a stearate derivative, advantageously a stearate or stearyl fumarate salt, more advantageously sodium stearyl fumarate or magnesium stearate.

Solid dosage forms of vigabatrin

Method for treating crohn's disease using triple antimicrobial all-in-one formulation

Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to,subspeciesinfection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.

Methods of treating a bacterial infection using a fixed-dose pharmaceutical composition comprising three antibiotics

[object Object]

Pharmaceutical compositions comprising three antibiotics

Compositions comprising rifabutin, clarithromycin, and clofazimine and uses thereof

Growing community of inventors

Laval, Canada

Patrick Gosselin